Orgenesis Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Orgenesis are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Orgenesis has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable technical and fundamental indicators, Orgenesis is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 6.4 M |
Orgenesis |
Orgenesis Relative Risk vs. Return Landscape
If you would invest (100.00) in Orgenesis on April 27, 2025 and sell it today you would earn a total of 100.00 from holding Orgenesis or generate -100.0% return on investment over 90 days. Orgenesis is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Orgenesis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orgenesis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orgenesis' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Orgenesis, and traders can use it to determine the average amount a Orgenesis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ORGS |
Based on monthly moving average Orgenesis is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orgenesis by adding Orgenesis to a well-diversified portfolio.
Orgenesis Fundamentals Growth
Orgenesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Orgenesis, and Orgenesis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orgenesis Pink Sheet performance.
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 530 K | ||||
| EBITDA | (54.07 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Book Value Per Share | (3.30) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Earnings Per Share | (8.00) X | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
Things to note about Orgenesis performance evaluation
Checking the ongoing alerts about Orgenesis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Orgenesis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orgenesis is not yet fully synchronised with the market data | |
| Orgenesis has some characteristics of a very speculative penny stock | |
| Orgenesis has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Orgenesis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orgenesis' stock is overvalued or undervalued compared to its peers.
- Examining Orgenesis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orgenesis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orgenesis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orgenesis' pink sheet. These opinions can provide insight into Orgenesis' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Orgenesis Pink Sheet
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |